Cyclic-di-GMP (Synonyms: c-di-GMP; cyclic diguanylate; 5GP-5GP)

Cat. No.: HY-107780: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Cyclic-di-GMP is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP can be used in cancer research.

The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Cyclic-di-GMP disodium and Cyclic-di-GMP diammonium) that retains the same biological activity.

For research use only. We do not sell to patients.

Cyclic-di-GMP Chemical Structure

CAS No. : 61093-23-0

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Cyclic-di-GMP:

5 Publications Citing Use of MCE Cyclic-di-GMP

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

STING^[1]^[2]^[3]^[4].

In Vitro

Cyclic-di-GMP (0.5-50 µM; 5 days) inhibits proliferation of human colon cancer cells^[1].
Cyclic-di-GMP (0.5-50 µM; 5 days) specifically elevates CD4 expression in Jurkat cells^[2].
Cyclic-di-GMP (0.5-50 µM; 5 days) induces cell cycle arrest at the S-phase in Jurkat cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	H508 cells
Concentration:	0.5-50 µM
Incubation Time:	5 days
Result:	Reduced basal H508 cell proliferation by approx 15%, even inhibited acetylcholine- and EGF-induced cell proliferation.

Cell Viability Assay^[2]

Cell Line:	Jurkat cells
Concentration:	50 µM
Incubation Time:	24 h
Result:	Specifically induced of CD4 (no effect on the expression of CD8), with a 6.3-fold upregulation over control and in a dose-dependent manner.

Cell Cycle Analysis^[2]

Cell Line:	Jurkat cells
Concentration:	50 µM
Incubation Time:	24 h
Result:	Increased the percentage of cells in S-phase by 79%, with almost complete disappearance of G2/M-phase cells which decreased by 93%.

In Vivo

Cyclic-di-GMP (100 µg/per; i.v.; two sequential vaccinations 9 days apart) enhances TriVax-induced immune responses to melanoma in mice and further increased the anti-tumor effects of TriVax^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 (B6) mice (8- to 10-week-old)^[3].
Dosage:	100 µg/per
Administration:	Intravenous injection; two sequential vaccinations 9 days apart; combine with TriVax.
Result:	Significantly higher numbers of antigen-specific CD8 T cells when combined with TriVax. (TriVax consisted of a mixture of 120 μg Pam-hgp100, 100 µg hgp100 or 100 µg Ova, 50 or 25 μg anti-CD40 antibody, and 25 μg Poly-IC). Enhanced the anti-tumor activity of TriVax.

Molecular Weight

690.41

Formula

C₂₀H₂₄N₁₀O₁₄P₂

CAS No.

61093-23-0

Appearance

Solid

Color

White to off-white

SMILES

O[C@@H]([C@H](N1C=NC2=C1N=C(N)NC2=O)O3)[C@H](OP(O)(OC[C@@H]4[C@H]([C@H]([C@H](N5C=NC6=C5N=C(N)NC6=O)O4)O)O7)=O)[C@H]3COP7(O)=O

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Microorganisms

Endogenous metabolite

bacterial species

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

H₂O : ≥ 25 mg/mL (36.21 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.4484 mL	7.2421 mL	14.4841 mL
5 mM	0.2897 mL	1.4484 mL	2.8968 mL
10 mM	0.1448 mL	0.7242 mL	1.4484 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 98.18%

Select Batch:

Data Sheet (283 KB) SDS (252 KB)

COA (254 KB) HNMR (196 KB) LCMS (774 KB)

Handling Instructions (2659 KB)

References

[1]. Karaolis DK, et al. 3',5'-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochem Biophys Res Commun. 2005 Apr 1;329(1):40-5. [Content Brief]

[2]. Steinberger O, et al. Elevated expression of the CD4 receptor and cell cycle arrest are induced in Jurkat cells by treatment with the novel cyclic dinucleotide 3',5'-cyclic diguanylic acid. FEBS Lett. 1999 Feb 5;444(1):125-9. [Content Brief]

[3]. Wang Z, et al. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol Immunother. 2015 Aug;64(8):1057-66. [Content Brief]

[4]. Jenal U, et al. Cyclic di-GMP: second messenger extraordinaire. Nat Rev Microbiol. 2017 May;15(5):271-284. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	1.4484 mL	7.2421 mL	14.4841 mL	36.2104 mL
	5 mM	0.2897 mL	1.4484 mL	2.8968 mL	7.2421 mL
	10 mM	0.1448 mL	0.7242 mL	1.4484 mL	3.6210 mL
	15 mM	0.0966 mL	0.4828 mL	0.9656 mL	2.4140 mL
	20 mM	0.0724 mL	0.3621 mL	0.7242 mL	1.8105 mL
	25 mM	0.0579 mL	0.2897 mL	0.5794 mL	1.4484 mL
	30 mM	0.0483 mL	0.2414 mL	0.4828 mL	1.2070 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Cyclic-di-GMP Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks